

Date: Tuesday, December 29 2020 03:52 PM
Subject: [EXTERNAL] RE: CADN Immediate Action Regarding [REDACTED] ABO
From: [REDACTED] <[REDACTED]@dnwest.org>
To: [REDACTED] <[REDACTED]@unos.org>;
CC: [REDACTED] <[REDACTED]@dnwest.org>;
Attachments: image001.jpg; image002.jpg; image003.jpg; image004.jpg

Hi [REDACTED]

We will ensure to add that expertise.

Thank you,

[REDACTED]

From: [REDACTED] <[REDACTED]@unos.org>
Sent: Tuesday, December 29, 2020 11:54 AM
To: [REDACTED] <[REDACTED]@dnwest.org>
Cc: [REDACTED] <[REDACTED]@dnwest.org>
Subject: RE: CADN Immediate Action Regarding [REDACTED] ABO

[REDACTED] and [REDACTED]

Good afternoon – I discussed this case with the MPSC Chairs today, and they recommend that a transfusion specialist or hematologist be included in your internal investigation of this case, if that has not already been done. I just wanted to pass that along to you.

Please let me know if you have any questions.

[REDACTED]
Safety Analyst



Matching organs. Saving lives.

[REDACTED]@unos.org

[REDACTED]

[REDACTED]

www.unos.org   

CONFIDENTIAL MEDICAL PEER REVIEW CONTENT/CONFIDENTIALITY STATEMENT

This electronic message transmission may include information that is confidential. If you are not the intended recipient, be aware that disclosure, copying, distribution or use of all or any portion of the content of this information is prohibited, except by authority of the sender. If you received this transmission in error, please notify us as soon as possible by e-mail and delete the original message.

From: [REDACTED] <[REDACTED]@dnwest.org>
Sent: Sunday, December 27, 2020 6:34 PM
To: [REDACTED] <[REDACTED]@unos.org>
Cc: [REDACTED] <[REDACTED]@dnwest.org>
Subject: [EXTERNAL] Re: CADN Immediate Action Regarding [REDACTED] ABO

Certainly.

[REDACTED]
[REDACTED]
V.P. of Quality Systems

[REDACTED]
[REDACTED]



On Dec 27, 2020, at 14:35, [REDACTED] <[REDACTED]@unos.org> wrote:

Thanks. I appreciate you getting back to me over the holiday weekend.

Sent with BlackBerry Work (www.blackberry.com)

From: [REDACTED] <[REDACTED]@dnwest.org>
Sent: Dec 27, 2020 5:33 PM
To: [REDACTED] <[REDACTED]@unos.org>
Cc: [REDACTED] <[REDACTED]@dnwest.org>
Subject: [EXTERNAL] RE: CADN Immediate Action Regarding [REDACTED] ABO

Hi [REDACTED]

Upon review of our process, we see a few possible gaps:

- 2.1.4.2.1. says "All available typing and subtyping results must be assessed and found to be equivalent (e.g. hospital results, first laboratory result, second laboratory result)". We think we may not have recognized cancelled tests as a "result", and in general not considered all results.
- 2.1.4.6.2 indicates resolving discrepancy by testing at donor hospital "or" other designated testing site. This conflicts with the following bullet that indicates using the guidelines, which indicate testing at hospital and an outside lab.
- 2.2.2.2 indicates a huddle if discrepancies cannot be resolved

The interim instructional statement says:

- "All ABO tests must be considered when determining a donor's blood type. If any test indicates anything other than a conclusive result (including cancellation), or is in any way inconsistent with other ABO testing; all results must be reviewed by organ program clinical leadership and must follow SE-M-001, Section 2.2, Guidelines for Handling Conflicting Primary Blood Type Results. This includes testing by an outside (non-hospital) lab"

We believe this statement emphasizes the need to consider all results as stated in 2.1.4.2.1; it addresses 2.1.4.6.2 by requiring a result from an outside lab, and it indicates a huddle much earlier in the process (when conflicting results are identified).

Again, please recognize we are still in the discovery process.

Thank you,

[REDACTED]

-----Original Message-----

From: [REDACTED] <[REDACTED]@unos.org>
Sent: Sunday, December 27, 2020 12:27 PM
To: [REDACTED] <[REDACTED]@dnwest.org>
Cc: [REDACTED] <[REDACTED]@dnwest.org>
Subject: RE: CADN Immediate Action Regarding [REDACTED] 1 ABO

Thank you - this has been received.

Can you describe what makes this interim process different from the usual way ABO discrepancies were resolved? What I will be asked about is how this is a change in the process, and I need to be sure I am articulating that clearly.

[REDACTED]

Safety Analyst

[REDACTED]@unos.org
[REDACTED]

-----Original Message-----

From: [REDACTED] <[REDACTED]@dnwest.org>
Sent: Sunday, December 27, 2020 2:56 PM
To: [REDACTED] <[REDACTED]@unos.org>
Cc: [REDACTED] <[REDACTED]@dnwest.org>
Subject: [EXTERNAL] RE: CADN Immediate Action Regarding [REDACTED] 1 ABO

Hi [REDACTED]

Attached is our protocol.

Hi [REDACTED]

Please see the attached section from our manual relating to testing and resolving ABO discrepancies.

We have amended our previous interim instruction as follows: "All ABO tests must be considered when determining a donor's blood type. If any test indicates anything other than a conclusive result (including cancellation), or is in any way inconsistent with other ABO testing; all results must be reviewed by organ program clinical leadership and must follow SE-M-001, Section 2.2, Guidelines for Handling Conflicting Primary Blood Type Results. This includes testing by an outside (non-hospital) lab"

We feel this will ensure all results are considered, conflicts are resolved per procedure including the use of an outside lab, and donors are listed conservatively based on all testing. We are open to additional action if warranted.

Thank you,

██████████
-----Original Message-----

From: ██████████ <██████████unos.org>
Sent: Thursday, December 24, 2020 5:56 PM
To: ██████████ <██████████dnwest.org>
Cc: ██████████ <██████████@dnwest.org>
Subject: RE: CADN Immediate Action Regarding ██████████ ABO

██████████ by Sunday night could you please send me your protocols for resolving indeterminate ABO, and what change in that protocol is involved in the description below?

Sent with BlackBerry Work (www.blackberry.com <<http://www.blackberry.com>>)

From: ██████████ <██████████dnwest.org>
Sent: Dec 24, 2020 3:09 PM
To: ██████████ <██████████unos.org>
Cc: ██████████ <██████████@dnwest.org>
Subject: [EXTERNAL] CADN Immediate Action Regarding ██████████ ABO

Hi ██████████

We are instructing our organ clinical leadership as follows:

Effective immediately, any ABO test that indicates anything other than a conclusive result, or is in any way inconsistent with other ABO testing; must be reviewed by organ program clinical leadership.

Please reply to acknowledge receipt.

Our early review of the event, in context of our existing procedure, indicates this will prevent recurrence in the short term as we continue our detailed assessment.

Any input is welcomed.

Thank you,

██████████

██████████ CEBT, CTBS
V.P of Quality Systems
██
██

[cid:image007.png@01D45CAD.8A8F6D20] <<https://www.donornetworkwest.org/>>

Confidentiality Note: This e-mail message contains information from the Donor Network West that may be privileged and/or confidential. If you are not the addressee or an authorized recipient of this message,

any distribution, copying, publication, or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.

Confidentiality Note: This e-mail message contains information from the Donor Network West that may be privileged and/or confidential. If you are not the addressee or an authorized recipient of this message, any distribution, copying, publication, or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.

Confidentiality Note: This e-mail message contains information from the Donor Network West that may be privileged and/or confidential. If you are not the addressee or an authorized recipient of this message, any distribution, copying, publication, or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.

Confidentiality Note: This e-mail message contains information from the Donor Network West that may be privileged and/or confidential. If you are not the addressee or an authorized recipient of this message, any distribution, copying, publication, or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.

Confidentiality Note: This e-mail message contains information from the Donor Network West that may be privileged and/or confidential. If you are not the addressee or an authorized recipient of this message, any distribution, copying, publication, or use of this information for any purpose is prohibited. Please notify the sender immediately by e-mail and then delete this message.